Coagulation Factor Concentrates Market to reach US$ 11.4 Billion by 2027, Expanding at a CAGR of 7.8%: Fact.MR

At present, the worldwide coagulation factor concentrates market is valued at $7.8 billion. According to the Fact.MR industry assessment, sales of coagulation factor concentrates will grow at a respectable CAGR of 7.8% between 2022 and 2027.

Growing prevalence of blood disorders and increased expenditure in healthcare R&D are likely to boost coagulation factor concentrates market expansion over the next five years. Other variables that may drive coagulation factor concentrate sales until 2027 include government measures to raise knowledge about blood diseases, increased use of prophylactic medication, and a high incidence of hemophilia.

However, a lack of awareness regarding blood disorders in emerging and developing nations is projected to limit market growth to some extent.

For Critical Insights on Coagulation Factor Concentrates Market, Request a Sample Report
https://www.factmr.com/connectus/sample?flag=S&rep_id=7677

Rising adoption of prophylaxis treatment, rising incidence of hemophilia in newborns, increased demand for hemophilia treatment, and high investments in healthcare research and development are all potential drivers of coagulation factor concentrates market growth over the next five years.

However, high blood disease treatment costs and a lack of knowledge of blood disorders in developing nations are expected to have a negative impact on the overall coagulation factor concentrates market potential.

How Will the Coagulation Factor Concentrates Industry Fare Across Geographies?

"North America & Europe to Spearhead Global Coagulation Factor Concentrates Market Growth"

The North American coagulation factor concentrates market is expected to hold a significant market share in the worldwide business landscape throughout the forecast period.

Rapid acceptance of novel treatments, the availability of sophisticated healthcare infrastructure, and increased investments in the healthcare R&D sector are likely to significantly boost coagulation factor concentrate demand in this area through 2027. The market for coagulation factor concentrates in Canada is expected to grow at a 6.4% CAGR over the next five years.

Investments in healthcare infrastructure and increased government support to raise awareness of blood diseases are projected to boost coagulation factor concentrate sales in Europe in the coming years. France, Italy, Germany, and the United Kingdom are key countries for coagulation factor concentrate suppliers to monitor in this region.

The Germany coagulation factor concentrates market is expected to grow at a CAGR of approximately 4.5% through 2027.

The Asia Pacific coagulation factor concentrates market is expected to grow due to an expanding patient population affected by blood-related disorders and increased expenditure in healthcare infrastructure development. India is expected to be an important market for coagulation factor concentrates due to the country's high prevalence of hemophilia.

𝐑𝐞𝐚𝐝 𝐌𝐨𝐫𝐞: https://www.factmr.com/report/coagulation-factor-concentrates-market

Key Segments Covered in the Coagulation Factor Concentrates Industry Survey

By Type :

Coagulation Factor IX
Coagulation Factor XIII
Other Types

By End User :

Hospitals & Clinics
Research Laboratories
Academic Institutions

By Region :

North America
Latin America
Europe
APAC
MEA

Competitive Landscape

Coagulation factor concentrate providers are working on increasing their income generation capacity by obtaining additional regulatory approvals for their goods.

In July 2022, Novo Nordisk, a Danish multinational pharmaceutical company, stated that the US Food and Drug Administration (FDA) has approved REBINYN®, Coagulation Factor IX, GlycoPEGylated for routine prophylaxis in adults and children. REBINYN is a concentration made from recombinant DNA that contains coagulation factor IX.
In addition, this new market analysis on the coagulation factor concentrates business includes latest advances by important firms such as Baxter International Inc., Octapharma, LFB, Biotest, Green Cross Corporation, Shanghai RAAS Blood Products, and Sanquin.

Winning Strategy

Companies that manufacture coagulation factor concentrates are expected to focus on increasing their research scope and obtaining regulatory approval for their goods.

This new Fact.MR coagulation factor concentrates market assessment provides a complete account of all the strategies used by big and minor industry participants.

Get Customization on Coagulation Factor Concentrates Market Report for Specific Research Solutions
https://www.factmr.com/connectus/sample?flag=RC&rep_id=7677

Key players in the Coagulation Factor Concentrates Market

CSL Behring
Shire
Kedrion S.P.A.
Grifols
Baxter International Inc.
Octapharma
LFB
Novo Nordisk A/S
Biotest
Key Takeaways from Coagulation Factor Concentrates Market Study

The global market valuation for coagulation factor concentrates is $7.8 billion.
Demand for coagulation factor concentrates is expected to grow at a 7.8% CAGR until 2027.
By 2027, the market is expected to reach $11.4 billion.
Increasing healthcare spending, rising hemophilia prevalence, increased investments in healthcare R&D, and supportive government activities to raise awareness about blood diseases are all likely to enhance market growth.
The US market for coagulation factor concentrates is now valued at $2 billion.
High blood disorder treatment costs and tight regulatory requirements are projected to limit market potential to some extent.
The Chinese coagulation factor concentrates market is expected to be worth $2.5 billion by the end of 2027.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

𝐀𝐛𝐨𝐮𝐭 𝐅𝐚𝐜𝐭.𝐌𝐑

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.